Pharmacology of disulfiram - An update;Klinische pharmakologie von disulfiram - Eine aktuelle übersicht

Fortschritte der Neurologie Psychiatrie

Volumn 76, Issue 4, 2008, Pages 225-231

  Mutschler, J ^a   Diehl, Alexander ^a   Kiefer, F ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Adverse drug reactions; Alcohol; Disulfiram; Drug interactions; Side effects

Indexed keywords

ACAMPROSATE; DISULFIRAM; NALTREXONE; ANTIDEPRESSANT AGENT; DRUGS USED IN THE TREATMENT OF ADDICTION;

ADDICTION; ALCOHOL ABSTINENCE; DRUG MECHANISM; HUMAN; REVIEW; AGED; ALCOHOLISM; CASE REPORT; DRUG COMBINATION; DRUG INTERACTION; MALE; PSYCHOLOGICAL ASPECT;

AGED; ALCOHOL DETERRENTS; ALCOHOLISM; ANTIDEPRESSIVE AGENTS; DISULFIRAM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MALE;

EID: 45149095856     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1016438     Document Type: Review

References (57)

1. De Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 2004; 39: 528-531
2. De Sousa A, De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2005; 40: 545-548
3. Krampe H, Stawicki S, Wagner T et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 2006; 30: 86-95
4. Chick J, Gough K, Falkowski W et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992; 161: 84-89
5. Datenlieferungen nach § 300 SGB V, Wissenschaftliches Institut der AOK WldO. 2007
6. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 15-26
7. Brewer C. How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice. Br J Psychiatry 1984; 144: 200-202
8. Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22: 1212-1219
9. Elenbaas RM. Drug therapy reviews: management of the disulfiram-alcohol reaction. Am J Hosp Pharm 1977; 34: 827-831
10. Amadoe M, Gazdar A. Sudden death during disulfiram-alcohol reaction. Q J Stud Alcohol 1967; 28: 649-654
11. Guild J, Epstein NB. Psychosis during the treatment of alcoholism with tetraethylthiuram disulfide. Q J Stud Alcohol 1951; 12: 360-366
12. Jacobsen E. Deaths of alcoholic patients treated with disulfiram (tetraethylthiuram disulfide) in Denmark. Q J Stud Alcohol 1952; 13: 16-26
13. Fuller RK, Branchey L, Brightwell DR et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256: 1449-1455
14. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004; 99: 21-24
15. Green AL. The inhibition of dopamine-B-oxidase by chelating agents. Biochem biophys Acta 1964; 81: 394-397
16. Mays DC, Ortiz-Bermudez P, Lam JP, Tong IH, Fauq AH, Lipsky JJ. Inhibition of recombinant human mitochondrial aldehyde dehydrogenase by two intermediate metabolites of disulfiram. Biochem Pharmacol 1998; 55: 1099-1103
17. Karamanakos PN, Pappas P, Stephanou P, Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol Toxicol 2001; 88: 106-110
18. Musacchio JM, Goldstein M, Anagnoste B, Poch G, Kopin IJ. Inhibition of dopamine-beta-hydroxylase by disulfiram in vivo. J Pharmacol Exp Ther 1966; 152: 56-61
19. Paradisi R, Grossi G, Pintore A et al. Evidence for a pathological reduction in brain dopamine metabolism in idiopathic hyperprolactinemia. Acta Endocrinol (Copenh) 1991; 125: 246-252
20. Rosen GF, Lobo RA. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1987; 65: 891-895
21. Amit Z, Levitan DE, Lindros KO. Suppression of ethanol intake following administration of dopamine-beta-hydroxylase inhibitors in rats. Arch Int Pharmacodyn Ther 1976; 223: 114-119
22. Kohnke MD, Zabetian CP, Anderson GM et al. A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry 2002; 52: 1151-1158
23. Kohnke MD, Kolb W, Kohnke AM, Lutz U, Schick S, Batra A. DBH*444G/A polymorphism of the dopamine-beta-hydroxylase gene is associated with alcoholism but not with severe alcohol withdrawal symptoms. J Neural Transm 2006; 113: 869-876
24. Ewing JA, Rouse BA, Mueller RA, Silver D. Can dopamine beta-hydroxylase levels predict adverse reactions to disulfiram? Alcohol Clin Exp Res 1978; 2: 93-94
25. Heath RG, Nesselhof Jr W, Bishop MP, Byers LW. Behavioral and metabolic changes associated with administration of tetraethylthiuram disulfide (antabuse). Dis Nerv Syst 1965; 26: 99-105
26. Major LF, Lerner P, Ballenger JC, Brown GL, Goodwin FK, Lovenberg W. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 1979; 14: 337-344
27. Cubells JF, Kranzler HR, Cance-Katz E et al. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry 2000; 5: 56-63
28. Poikolainen K. The disulfiram-ethanol reaction (DER) experience. Addiction 2004; 99: 6-28
29. Ehrenreich H, Krampe H. Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram's psychological effects. Addiction 2004; 99: 26-27
30. Martensen-Larsen O. Psychotic phenomena provoked by tetraethylthiuram disulfide. Q J Stud Alcohol 1951; 12: 206-216
31. Christensen JK, Ronsted P, Vaag UH. Side effects after disulfiram. Comparison of disulfiram and placebo in a double-blind multicentre study. Acta Psychiatr Scand 1984; 69: 265-273
32. Fuller RK, Branchey L, Brightwell DR et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256: 1449-1455
33. Poulsen HE. Disulfiram therapy - adverse drug reactions and interactions. Loft S, Andersen JR, Andersen M (eds). Acta Psychiatr Scand 1992; 86: 59-66
34. Branchey L, Davis W, Lee KK, Fuller RK. Psychiatric complications of disulfiram treatment. Am J Psychiatry 1987; 144: 1310-1312
35. Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006; 44: 791-797
36. Frisoni GB, Di Monda V. Disulfiram neuropathy: a review (1971-1988) and report of a case. Alcohol Alcohol 1989; 24: 429-437
37. Berglund M. A better widget? Three lessons for improving addiction treatment from a meta-analytical study. Addiction 2005; 100: 742-750
38. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28 (1): 51-63
39. Kiefer F, Jahn H, Tarnaske T et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92-99
40. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22: 573-579
41. Landabaso MA, Iraurgi I, Sanz J et al. Naltrexone in the treatment of alcoholism. Two-year follow up results. Eur J Psychiatry 1999; 13: 97-105
42. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005; 57: 1128-1137
43. Petrakis IL, Poling J, Levinson C et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry 2006; 60: 777-783
44. Weinshenker D, Schroeder JP. There and Back Again: A Tale of Norepinephrine and Drug Addiction. Neuropsychopharmacology 2007; 32: 1433-1451
45. Finney JW, Monahan SC. The cost-effectiveness of treatment for alcoholism: a second approximation. J Stud Alcohol 1996; 57: 229-243
46. Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002; 97: 265-277
47. Fuller RK, Branchey L, Brightwell DR et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256: 1449-1455
48. Kellam AM, Wesolkowski JM. Disulfiram implantation for alcoholism. Lancet 1968; 1: 925-926
49. Wilson A, Davidson WJ, Blanchard R, White J. Disulfiram implantation. A placebo-controlled trial with two-year follow-up. J Stud Alcohol 1978; 39: 809-819
50. Hughes JC, Cook CC. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92: 381-395
51. Suh JJ, Pettinati HM, Kampman KM, O''Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26: 290-302
52. Matching Alcoholism Treatments to Client Heterogeneity. Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997; 58: 7-29
53. Moos RH, Finney JW, Ouimette PC, Suchinsky RT. A comparative evaluation of substance abuse treatment: I. Treatment orientation, amount of care, and 1-year outcomes. Alcohol Clin Exp Res 1999; 23: 529-536
54. Brewer C. Long-term, high-dose disulfiram in the treatment of alcohol abuse. Br J Psychiatry 1993; 163: 687-689
55. Carroll KM, Fenton LR, Ball SA et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 264-272
56. Fritze J. Psychopharmaka-Verordnungen - Ergebnisse und Kommentare zum Arzneiverordnungsreport 2005. Psychoneuro 2006; 32: 44-53
57. Kiefer F, Jahn H, Holzbach R, Briken P, Stracke R, Wiedemann K. Die NALCAM-Studie: Wirksamkeit, Verträglichkeit, Outcome. Sucht 2003; 49 (6): 342-351